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BACKGROUND: Interferon is approved for adjuvant treatment of patients with stage IIB/III melanoma. The identification
of predictive markers that would permit selection of patients would be beneficial. Specific human leukocyte antigen
(HLA) class I and II antigens have previously shown an association with response to therapy or overall survival of patients
with metastatic melanoma. METHODS: A total of 284 high-risk melanoma patients participating in a randomized trial and
246 healthy controls were molecularly typed for HLA class I and II. Specific allele frequencies were compared between the
healthy and patient populations, as well as presence or absence of these in relation to recurrence. Alleles related to auto-
immune disease were also investigated. RESULTS: No significant differences were found between the distribution of
HLA genotype in the melanoma population compared with healthy controls. Correlations between nonrecurrence and
the presence of HLA-Cw*06 allele were noted present in 19.3% of melanoma patients. The median relapse-free survival
of the Cw*06-positive cohort was 100.2 months versus 37.3 months in the Cw*06-negative cohort (P ¼.013).The median
overall survival for the Cw*06-positive cohort has not yet been reached, versus 78.9 months in the Cw*06-negative
cohort (P ¼ .025). HLA-Cw*06 was present in 29.79% of patients in the autoimmunity group and 15.38% of patients in
the nonautoimmunity group (P ¼.049). CONCLUSIONS: No allele was associated with absence of recurrence in patients
receiving adjuvant interferon with the exception of HLA-Cw*06, an allele correlated with psoriasis. HLA-Cw*06-positive
patients have better relapse-free and overall survival.Cancer 2010;116:4326–33.V C 2010 American Cancer Society.
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Patients with stage IIB, IIC, and III melanoma as defined by the American Joint Committee on Cancer (AJCC sixth
edition) are characterized as a group at high risk, with relapse and mortality risks exceeding 40% at 5 years.
1 Several large
cooperative group trials have evaluated adjuvant therapy with high-dose interferon (IFN)-a2b in this patient population
and have consistently demonstrated significant prolongation of relapse-free survival (RFS) as compared with observation
or GM2 coupled to keyhole limpet hemocyanin (KLH) and combined with the QS-21 adjuvant (GMK)-vaccine.
2-4 Two
of these trials have also demonstrated a significant improvement in overall survival (OS).
2,4 The pooled analysis of 4 East-
ern CooperativeOncology Groupand intergrouptrials conducted between1984 and 2001has showna durable impactof
high-dose IFN on RFS, but not on OS.
5 Analyses of the RFS and OS curves from the initial trial (E1684) revealed early
separation between the high-dose IFN-a2b and the observation arms.
2 Therefore, the 1-month intravenous induction
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Original Articlephase of the regimen may be necessary and sufficient to
reduce the risk of recurrence, and several prospective trials
designed to test this hypothesis are currently ongoing or
have recentlybeenreported.
6
Unfortunately, acceptance of high-dose IFN-a2b
has been limited because of the toxicity and cost of this
regimen and the lack of a large survival benefit in meta-
analyses.
7,8Evidencesuggeststhatonlyasubsetofpatients
will benefit from this therapy. Nearly all patients experi-
ence side effects, including fatigue, fever, arthralgia, ano-
rexia, hepatic toxicity, and depression that can be severe.
A better understanding of the mechanism of action of
IFN-a2b and identification of predictive markers that
would permit selection of patients most likely to benefit
wouldthereforebe beneficial.
Serological typing for both human leukocyte anti-
gen (HLA) class I and class II antigen expression has
previously shown an association between specific HLA
antigen expression and clinical response to therapy or OS
of patients with metastatic melanoma treated with inter-
leukin (IL)-2 (eg, HLA-DQ1)
9,10 or combinations of
IFN-a and IL-2.
11 One report demonstrated an associa-
tion of homozygosity of HLA-DR and decreased chance
of response to treatment with IL-2.
12 The purpose of the
present study was to evaluate the role that HLA class I
or major histocompatibility complex I (determined at
low resolution) and HLA-DR/DQ or major histocompat-
ibility complex II (determined at high-resolution) might
exert on the outcome of high-risk melanoma patients
receiving adjuvant high-dose interferon. The patients
included in this analysis were a subgroup of patients en-
rolled in a randomized phase 3 trial conducted by the
Hellenic Cooperative Oncology Group to evaluate intra-
venous induction therapy with interferon alfa-2b for 4
weeks as compared with the same regimen followed by
11 months of adjuvant interferon alfa-2b therapy.
In addition, we compared HLA frequencies in mela-
noma patients and healthy controls (healthy unrelated
individuals from the Donor Marrow Registry of the
National Tissue Typing Center, Athens, Greece). Fur-
thermore, because an increased risk of developing disease
recurrence as well as second primary melanomas in mela-
noma patients presenting with localized disease has been
associated with HLA-DQB1*0301 or HLA-DRB1*1101
alleles,
13-16 we compared the frequency of these genotypes
in 2 groups of melanoma patients defined by outcome—
namely, those who remained free of recurrence and those
who have experienced disease recurrence. HLA alleles
related to the development of autoimmune diseases
17
were studied as a consequence of our observation of corre-
lations between autoimmunity and disease outcome on
treatmentwithIFN.
MATERIALS AND METHODS
Patients
Blood samples were collected with ACD anticoagulant
from 284 melanoma patients and a panel of 246 ran-
domly selected healthy unrelated Greek individuals, who
servedas acontrolpopulation.
Patients participating in this study were enrolled in
Trial 13A/98, a prospective, multicenter, randomized
phase 3 trial conducted at 13 institutions by the Hellenic
Cooperative Oncology Group. In this trial, 364 patients
withhistologicallydocumented AJCC stage IIB,IIC, orIII
primary cutaneous melanoma were enrolled between 1998
and 2004. For patients with clinically negative lymph
nodes, stage was defined pathologically using sentinel
lymph node (SLN) biopsy. Any patient with a positive
SLNwasrequiredtoundergocompletelymphadenectomy.
All patients were randomized to receive protocol treatment
within 2 months of initial surgery or 1.5 months of thera-
peutic lymph node dissection. The regimen used was a
modification of the E1684 regimen.
6 Group A patients
received IFN-a2b (15 MIU/m
2/d intravenously 5 days per
week for 4 weeks) followed by observation. Group B
patients received the same induction dose for 4 weeks fol-
lowed by subcutaneous therapy (10 MIU/day 3 /wk) for
an additional 48 weeks. The primary endpoint for the core
protocolwasRFSandOSbytreatmentgroup.
The HLA substudy reported here was conducted
prospectively at 4 institutions participating in the core
protocol. This substudy had separate institutional review
board approval, and all patients provided written
informed consent to this substudy. Blood samples for
evaluation of HLA were drawn at the same time as sam-
ples for routine initial visit clinical tests. The first 10 mL
of blood collected was used for standard biochemistry and
blood cell counts, and the second 3 mL was used for HLA
testing.Bloodsampleswere obtainedbeforetreatment.
The clinical outcome of patients was prospectively
followed using standardized testing. Clinical staging con-
sisted of medical history, physical exams, blood cell
counts, and blood biochemistry at 3-month intervals, and
chestx-rayand liverultrasoundat6-monthintervals.
Methods
DNA extraction
Genomic DNA was extracted and isolated from
whole peripheral blood of all patients and controls, using
HLA and Response to Interferon/Gogas et al
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ment for nucleic acid purification) and a genetic extrac-
tion kit, following the manufacturer’s protocol
(Genovision, Oslo, Norway; Qiagen, Hilden, Germany).
DNA was dissolved in doubly distilled H20, DNA con-
centration was estimated by measurement of OD260, and
purity was measured by the ratio of OD260/280. The
final preparation was stored at  20 C until further
analysis.
HLA Typing
Genomic HLA typing was performed using previ-
ously published DNA based techniques.
18-20 Initially
HLA-A, -B, -Cw, -DRB1, and -DQB1 low resolution
molecular typing was performed in all subjects, with
amplification of genomic DNA by polymerase chain reac-
tion (PCR) using locus-specific primers and reverse
hybridization with sequence and allele-specific oligonu-
cleotide probes, using a commercially available kit
(Lambda Array Beads Multi-Analyte System, LABType
RSS0, One Lambda, Inc., Canoga Park, Calif). Subse-
quently, high-resolution typing at the allele level of HLA-
DRB1 and -DQB1 loci was implemented by PCR using
sequence-specific oligonucleotides (ELPHA HiRes, Biot-
est, Dreieich, Germany) and PCR with sequence-specific
primers (Olerup SSP, Saltsjoebaden, Sweden), respec-
tively, following the manufacturers’ recommendations.
The allele assignment was made according to the HLA-
visual softwareprogram.
Statistical Analysis
Allele frequencies were defined with 2 different
approaches. In the first approach, each individual was
used as a unit, and a particular allele was noted as present
if detected at least once in an individual. In the second
approach,thetotalnumberofdetectionsofaparticularal-
lele was counted, that is, the allele presence was counted
once in heterozygous and twice in homozygous pheno-
types. In this case, the allele frequency was calculated over
twice the number of individuals tested. Specific allele fre-
quencies were calculated for both the patient population
and the healthy control population. Fisher exact test was
used for comparing the frequency of specific alleles (1 ob-
servation per patient) between the healthy and patient
populationsas wellas thefrequencyofrecurrencebetween
the population in which the specific allele was present ver-
sus thepopulationinwhichitwas absent.
In addition, recurrence and specific allele frequen-
cies were compared between patients with or without
development of autoimmunity.
21 Development of auto-
immunity was defined as either a positive test for autoan-
tibodies or presentation with a clinical manifestation of
autoimmunity in the 12-month period during which
blood samples were analyzed for autoantibodies. Two-
sided P values were used with no adjustment to account
for multiple comparisons. The analyses presented here
should be considered as exploratory and hypothesis gener-
ating rather than conclusive. The relationship between
presence of specific alleles, autoimmune response (land-
mark analysis at 12 months), and patient RFS and OS
were further studied using Cox proportional hazard mod-
els. The landmark analysis includes patients withoutevent
up to 12 months and still on follow-up at 12 months.
They are classified by whether they had autoimmunity,
based on their autoimmunity status at 12 months, that is,
after the last evaluation of autoimmunity was performed.
21
Survival was evaluated from the date protocol treatment
was started to the date of last follow-up or date of death
from any cause. RFS was calculated from the initiation of
treatment to the date on which relapse was first docu-
mented or on which death without documented relapse
occurred.Thereversecensoringmethodwasusedforcalcu-
lating descriptive statistics; for the follow-up time, Kaplan-
Meier estimates of RFS and OS are presented.
22 For all al-
leles presented, the ones with frequency <5% in the mela-
nomapopulationarenotincludedintheanalysis.
Alleles defined a priori were: HLA-A*02, HLA-
B*35, HLA-Cw*04, HLA-Cw*06, HLA-Cw*07, HLA-
DQB1*0301, HLA-DQB1*0501, *0502, *0503, *0504,
HLA-DQB1*0601, *0602, *0603, *0604, *0605, *0608,
*0609 (HLA DQB1*05 and HLA DQB1*06 correspond
to previously serologically typed HLA-DQ1), HLA-
DRB1*1101, HLA-DRB1*03, and HLA-DRB1*04. The
possibility of chance deviation still exists without correc-
tion, and for this reason we consider P values between .01
and .05 as probably significant, as suggested by others.
23
SAS 9.1 (SAS Institute, Cary, NC), was used for statistical
analysis, whereas RFS and OS curves were generated with
SPSSversion 15.
RESULTS
The frequency patterns of HLA class I and II were first
evaluated in the healthy control and melanoma popula-
tions. Eleven HLA alleles were found to be significantly
different between the melanoma patients and the healthy
control population. For the remainder, no significant dif-
ferences between the distribution of HLA genotype were
Original Article
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healthy control population. The alleles that differed
among melanoma patients were HLA-A*03, HLA-
B*037, *53, *54, *58, *59, *78, HLA-DRB1*1102,
HLA-DQB1*0201, and *0302 with corresponding
P values .042, .033, .050, .046, .001, .021, .004, .021,
.006and .033,respectively. Most of theseallelesarerepre-
sentedin <10%inboth populations.
Patient demographics and baseline characteristics
have been described elsewhere.
6,21 With a median follow-
up of 70.67 months (only among patients alive [censored
values], range, 7.1-138.7 months), there were 156 recur-
rences and 104 deaths. The association of HLA genotype
with absence of recurrence is presented in Table 1. Corre-
lations between nonrecurrence (alive/well vs recurrent/
dead) and the presence of MHCclass I allele HLA-Cw*06
and MHC class II allele HLA-DRB1*1501 were noted
with the corresponding P values .035 and .045, although
these are not corrected for multiple testing. When we
examined the gene frequency, no further information was
acquired on the predictive value of HLA. This was the
Table 1. Association Between HLA Genotype and Recurrence
in High-Risk Melanoma Patients Receiving Adjuvant
Interferon (Median Follow-up, 71 Months)
HLA-A No Evidence
of
Recurrence,
n 5 128
Recurred,
n 5 156
No. % No. %
Class I
A*01 25 19.53 39 25.00
A*02 60 46.88 73 46.79
A*03 14 10.94 16 10.26
A*11 13 10.16 20 12.82
A*23 6 4.69 13 8.33
A*24 40 31.25 39 25.0
A*26 18 14.06 14 8.97
A*30 8 6.25 9 5.77
A*32 15 11.72 27 17.31
A*33 11 8.59 11 7.05
A*68 8 6.25 7 4.49
HLA-B
B*07 11 8.59 14 8.97
B*08 8 6.25 13 8.33
B*13 12 9.38 6 3.85
B*15 4 3.13 12 7.69
B*18 34 26.56 36 23.08
B*35 33 25.78 50 32.05
B*37 7 5.47 8 5.13
B*38 11 8.59 5 3.21
B*39 12 9.38 10 6.41
B*40 8 6.25 11 7.05
B*44 18 14.06 19 12.18
B*51 24 18.75 44 28.21
B*52 7 5.47 9 5.77
B*55 9 7.03 12 7.69
B*57 8 6.25 6 3.85
B73 1 0.78 1 0.64
HLA-C
Cw*01 8 6.25 10 6.41
Cw*02 11 8.59 23 14.74
Cw*03 19 14.84 20 12.82
Cw*04 36 28.13 49 31.41
Cw*05 9 7.03 11 7.05
Cw*06 32 25 23 14.74
Cw*07 52 40.63 61 39.10
Cw*12 36 28.13 37 23.72
Cw*14 5 3.91 11 7.05
Cw*15 17 13.28 16 10.26
Cw*16 7 5.47 8 5.13
Class II
HLA-DRB1
DRB1*0101 11 8.59 16 10.26
DRB1*0301 17 13.28 22 14.10
DRB1*0701 23 17.97 19 12.18
DRB1*1101 19 14.84 27 17.31
DRB1*1104 46 35.94 54 34.62
DRB1*1301 15 11.72 10 6.41
DRB1*1302 8 6.25 12 7.69
DRB1*1401 9 7.03 14 8.97
DRB1*1501 10 7.81 25 16.03
(Continued)
Table 1. (Continued)
HLA-A No Evidence
of
Recurrence,
n 5 128
Recurred,
n 5 156
No. % No. %
DRB1*1502 6 4.69 8 5.13
DRB1*1601 38 29.69 36 23.08
HLA-DQB1
DQB1*0201 18 14.06 24 15.38
DQB1*0202 21 16.41 16 10.26
DQB1*0301 68 53.13 82 52.56
DQB1*0302 9 7.03 13 8.33
DQB1*0501 23 17.97 26 16.67
DQB1*0502 43 33.59 45 28.85
DQB1*0503 9 7.03 18 11.54
DQB1*0601 6 4.69 11 7.05
DQB1*0602 9 7.03 13 8.33
DQB1*0603 15 11.72 11 7.05
DQB1*0604 7 5.47 10 6.41
HLA indicates human leukocyte antigen.
The alleles A*25, A*29, A*31, A*66, A*69, A*80, B*14, B*27, B*41, B*45, B*47,
B*49, B*50, B*53, B*56, B*58, Cw*08, Cw*17, DRB1*0102, DRB1*0401,
DRB1*0402, DRB1*0403, DRB1*0405, DRB1*0408, DRB1*0801, DRB1*0802,
DRB1*0803, DRB1*0804, DRB1*1001, DRB1*1103, DRB1*1201, DRB1*1303,
DRB1*1321, DRB1*1404, DRB1*1407, DRB1*1503, DRB1*1602, DQB1*0302,
DQB1*0303, DQB1*0305, DQB1*0402, DQB1*0504, DQB1*0605, and DQB1*0609
with frequency <5% in the melanoma population are not included in the
analysis.
HLA and Response to Interferon/Gogas et al
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controlsand melanoma patients.
Comparison of RFS and OS for previously defined
alleles of interest also showed no statistically significant
difference among the other alleles investigated (A*02,
B*35, Cw*04, Cw*07, DQB1*0301, DRB1*1101,
DRB1*03, DRB1*04, DQB1*05 þ *06) with the excep-
tion of Cw*06. The median RFS of the Cw*06-positive
cohort was 100.2 months (range, 2.7-100.2; 95% confi-
dence interval [CI] not evaluable) versus 37.3 months in
the Cw*06-negative cohort (range, 1.1-115.1; 95% CI
21.1-53.5; P ¼ .013). The median OS of the Cw*06-pos-
itive cohort has not yet been reached (observed minimum
and maximum death times 9.8 and 84.2 months; 95% CI
not evaluable) versus 78.9 months in the Cw*06-negative
cohort (range, 2.3-86.1; 95% CI not evaluable), with a P
value of .025. Apart from HLA-Cw*06, stage was found
to be an independent predictor for RFS (P ¼ .029) and
OS (P ¼ .013) in univariate analysis. The association of
HLA-Cw*06 with RFS and OS was explored through a
multivariate Cox model including lymph node involve-
ment, ulceration, and stage. In the presence of HLA-
Cw*06 in the Cox model, only stage was found to be an
independent predictor for RFS (P ¼ .010) and OS (P ¼
.0011). Controlling for disease stage, the P values for the
association of Cw*06 with RFS and OS are .018 and
.039, respectively. Treatment duration and interaction of
treatment duration by HLA-Cw*06 were found nonsigni-
ficant, when included in the multivariate Cox models for
RFS and OS (P ¼ .20 and P ¼ .46, respectively for RFS;
P ¼ .33 and P ¼ .86, respectively for OS), along with
HLA-Cw*06 and autoimmunity. The Kaplan-Meier
curves for RFS and OS in the A*02 and Cw*06 cohorts
are presented in Figures 1 and 2. The median OS of the
B*35-positive cohort was 69.2 months (range, 8.0-86.1;
95% CI, 49.3-89.1) and has not yet been reached for the
B*35-negativecohort(range,2.3-84.2;95%CInotevalu-
able), with P ¼ .040 and P ¼ .1383 when controlling for
disease stage. No differences were observed in RFS (P ¼
.143andP¼ .2141whencontrolling fordiseasestage).
In the cohort of patients included in the prospective
autoimmunity study, allele frequency was investigated in
155 of 200 patients (47 in the autoimmunity group and
108 in the nonautoimmunity group). HLA-Cw*06 was
expressed in 29.79% (14 of 47) of patients in the autoim-
munity group and 15.38% (16 of 108) of patients in the
nonautoimmunity group (P ¼ .049). Statistical signifi-
cant differences were seen in HLA-B*35 (21.28% vs
41.35%; P ¼ .018) and HLA-DRB1*0701 (23.4% vs
7.69%; P ¼ .015, respectively). No differences were
seen in the expression of HLA-A*02 (31.91% vs 48.8%;
P¼ .077).
In the landmark model for the association of Cw*06
withRFS,Cw*06andautoimmunitywerestatisticallysig-
nificant (P ¼ .020 and P < .0001, respectively). In the
landmark model for the association of Cw*06 with OS,
only autoimmunity was statistically significant (P <
.0001). In the landmark models for the association of
HLA-B*35, HLA-DRB1*0701, and HLA-A*02 with
RFSorOS,onlyautoimmunitywasfoundstatisticallysig-
nificant (P < .0001). For all other cases, interaction
between alleles and autoimmunity was also tested, but it
wasfoundto beinsignificant.
DISCUSSION
This prospective analysis was performed to evaluate
whether HLA genotype influences the likelihood of a
Figure 1. (Top) Relapse-free survival plot shows human leuko-
cyte antigen (HLA)-A2 status (positive, n ¼ 133; negative, n ¼
151). (Bottom) Overall survival plot shows HLA-A2 status
(positive, n ¼ 133; negative, n ¼ 151).
Original Article
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To answer these questions, it was first necessary to define
a baseline population for comparison. No database was
available that describes the prevalence of HLA alleles
amongGreek melanoma patients.Severalreportshave an-
alyzed the HLA genotypes in North American Caucasian,
Italian, Spanish, and Scandinavian populations, yielding
conflicting data.
10,24-26 No significant differences were
seen in the HLA profiles of the Greek healthy control and
melanomapopulationsstudiedhere.
In the E2690 laboratory corollary of the intergroup
adjuvant trial E1690, among patients expressing HLA-
A*02, IFN-a2b treatment had a lesser impact on RFS
(P ¼ .02) compared with the observation arm; among
patients not expressing HLA-A*02, the RFS was better for
IFN-treated patients.
27 The differences did not reach sig-
nificance for RFS among patients in the HLA-A*02-nega-
tive subset because of the small size in the subset analyzed
from trial E1690 (P ¼ .16). The test for interaction
between treatment and HLA-A*02 status was marginally
significant (P ¼ .06). Therefore, this apparent interaction
may be a statistical artifact. In our group of patients, the
outcome of HLA-A*02-positive patients did not differ
from the HLA-A*02-negative cohort in terms both of
RFS and OS. Although patients in these 2 studies are of
different ethnic backgrounds (North American Caucasian
and Southern European Caucasian), and the methods
used for HLA typing differed (serological in the E2690
and molecular in the present), the percentages of HLA-
A*02 are similar; 42.7% and 46.8%, respectively. Like-
wise, other class I alleles such as A*11, or class II alleles
such as HLA-DQ1, an allele related to the susceptibility
to autoimmune diseases,
28 initially found to be associated
with clinical response and survival with IL-2 therapy in
the metastatic setting,
9,10 were not found to be related to
absence of recurrence in our group of patients. Interpreta-
tion of the results in the IL-2–treated patients should take
into consideration the caveats associated with retrospec-
tive studies involving a relatively limited number of
patients not homogenously treated along with uncor-
rected statistical correlations. Similarly, in our study there
are potential weaknesses in identifying differences in out-
come based on HLA status, possibly including a subset of
patients participating in a randomized trial in which half
of the patients received 1 month and half 1 year of adju-
vant interferon, as well as the mixed-stage patient popula-
tion. In addition, the large number of tests performed
exploring possible associations between HLA and disease,
recurrence, and autoimmune response would lead to
some significant results occurring by chance without bio-
logical significance. Thus, the analyses presented here
should be considered as exploratory and hypothesis gener-
ating rather than conclusive. Moreover, in an updated
report on 272 patients treated with IL-2–based therapy at
the National Institutes of Health, no significant associa-
tion between HLA type and response was observed.
12
However, in other immune strategies for melanoma such
as polyvalent melanoma, cell vaccine OS after treatment
correlated with HLA phenotypes.
29 However, it is impor-
tant to mention that both resolution and reliability of
molecular HLA typing has substantially improved during
the last decade, which has led to partial revisions in HLA
associations.
Similarly, no differences were seen when patients
were divided according to the presence or absence of HLA-
B*35, HLA-Cw*04, HLA-Cw*07, HLA-DRB1*301,
HLA-DRB1*04, or HLA-DRB1*1101, alleles associated
Figure 2. (Top) Relapse-free survival plot shows Cw6 status
(positive, n ¼ 55; negative, n ¼ 229). (Bottom) Overall sur-
vival plot shows Cw6 status (positive, n ¼ 55; negative, n ¼
229). HLA indicates human leukocyte antigen.
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ease),rheumatoidarthritis,Siccasyndrome,anddiabetes,
17
or HLA-DQB1*0301, previously correlated with recur-
rence in stage I and II melanoma patients. We investigated
HLA alleles that are correlated with a higher risk of specific
autoimmunediseases, as wehave previously shownthat the
appearance of autoantibodies and/or clinical signs of auto-
immunity are strongly associated with improved RFS and
OS in patients with melanoma who are receiving adjuvant
therapy with high-dose IFNa2b.
23 Failure to demonstrate
the association of thyroid autoimmunity with certain
HLA types in this study might in part be explained by the
finding that their presence increases the probability by no
more than 3-fold in most cases.
17 Moreover, this observa-
tion suggests that the IFNa2b-related induction of autoim-
munity in melanoma patients differs from spontaneously
occurring autoimmune disorders with respect to HLA
genetics and presumably also in other aspects of this multi-
factorial process. This is not surprising, because the current
understanding of the development of thyroid auto-
immunity suggests a T-cell–mediated disease with mostly
unknown multifactorial etiology, such as infection or
chronic inflammation with a strong genetic component.
30
Thus, different routes of autoimmunity may be associated
withdifferentsetsof genes.Nevertheless,itismostinterest-
ing that HLA-Cw*06-positive patients have better RFS
and OS (P ¼ .013 and P ¼ .025, respectively), which
remainsstatisticallysignificantforRFSeveninthepresence
of autoimmunity (P ¼ .020). In addition, a statistically
higher percentage of Cw*06-positive individuals was pres-
ent in the cohort of patientswhodeveloped autoimmunity.
Although the Cw*06 allele has been correlated with psoria-
sis, the IFNa2b-related autoimmunity was not limited to
theskin,affectingotherorgansaswell.
As none of the HLA class II alleles showed signifi-
cant positive or negative association with the exception of
Cw*06,thisresultis presentedheretoallowotherstocon-
sider the evaluation of this issue in trials of IFN-a2b that
arebeingconductedin separateUSand Europeancooper-
ative groups. In particular, as Cw*06-positive patients
may have slower-growing melanomas irrespective of IFN
therapy, this allele may thus be a prognostic rather than a
predictive marker. A validation set of non–IFN-treated
melanoma patients should be examined to evaluate this
hypothesis. The exploration of this finding in melanoma
patients matched for HLA type and adjusted for stage
from data sets of randomized controlled trials with an ob-
servation arm would answer this question. A final ques-
tion arises in regard to the correlation of Cw*06 and
favorable prognosis of melanoma: the expression of this
allele is also correlated with the development of psoriasis,
a proinflammatory disorder of the skin in which patients
areintolerantofIFNa.Itwasrecentlyshownthatthefrac-
tion of patients who benefitted from IFN therapy in the
randomized intergroup trial E1694 and were alive at 5 or
more years correlates with elevated pretreatment blood
serum levels of IL-6, tumor necrosis factor a, IL-1a, and
IL-1b.
31 The correlation of Cw*06 and elevation of
proinflammatory cytokines is thus a new topic of interest
inview ofthe findingsreportedinthisstudy.
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